Program
0 ppm F
Its studies are led by Procter and Gamble.
Furthest: phase 4, since Feb 9, 20212 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Procter and Gamble | 20 open or running | phase 4since Feb 9, 2021 | Feb 9, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2021First study: phase 4 study in CariesFirst studyNCT04763044 · 15 enrolled · United States
- Dec 11, 2024Phase 1 study in CariesNCT06735235 · 27 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06735235Caries · United States | 1 | Completed | Jul 29, 2021 | 27 |
| NCT04763044Caries · United States | 4 | Completed | Jul 21, 2021 | 15 |
How it is read
Names in the registry
- “0 ppm F”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.